pegnivacogin

Nucleic acidexperimental

Clinical trial activity

5 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Jun 1, 2005 (NCT00113997)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • pegnivacogin
  • pegnivacogin
  • pegnivacogin
  • pegnivacogin
  • rb006
  • rb006
  • rb006
  • rb 006
  • rb-006
  • rb006 compound
  • reg1
  • reg1
  • reg1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01848106Phase 3Sep 1, 2013Canadian VIGOUR Centre, Duke University, Icahn School of Medicine at Mount Sinai, Parexel, Regado Biosciences, University of Rochester
NCT01872572Phase 1Aug 1, 2009PPD, Regado Biosciences
NCT00932100Phase 2Jul 1, 2009Duke University, Regado Biosciences
NCT00715455Phase 2Oct 1, 2007Regado Biosciences
NCT00113997Phase 1Jun 1, 2005National Heart, Lung, and Blood Institute (NHLBI)
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Regado BiosciencesFor profit4432007
Duke UniversityAcademic/Hospital2022009
Canadian VIGOUR CentreAcademic/Hospital1012013
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012013
National Heart, Lung, and Blood Institute (NHLBI)Government1112005
ParexelFor profit1012013
PPDFor profit1012009
University of RochesterAcademic/Hospital1012013
8 organizations
Page 1 / 1